Objective assessment of immediate iodine-based contrast media hypersensitivity reactions using skin and drug provocation testing.

IF 1.1 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Si Min Chiow, Pearlyn Mei Ping Wong, Martin Weng Chin H'ng, Chau Hung Lee, Sze-Chin Tan
{"title":"Objective assessment of immediate iodine-based contrast media hypersensitivity reactions using skin and drug provocation testing.","authors":"Si Min Chiow, Pearlyn Mei Ping Wong, Martin Weng Chin H'ng, Chau Hung Lee, Sze-Chin Tan","doi":"10.1177/02841851251321476","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundWith increasing importance of iodine-based contrast media (ICM) in radiology, a label of allergy to ICM has significant impact on patient management, and objective testing for ICM allergy can help guide subsequent administration.PurposeTo correlate skin testing with drug provocation test (DPT) outcomes and determine cross-reactivity between our institution's three available ICMs.Material and MethodsEligible patients who presented to our institution's radiology department within a 3-year period with suspected ICM allergy were referred to the allergist for evaluation with skin testing ± DPT. Patients who tested negative were followed up to evaluate for any reaction after ICM re-exposure in subsequent contrast-enhanced computed tomography scans.ResultsA total of 72 cases underwent testing. Concordance between skin testing and DPT was 85.7% (6/7) for iohexol, 65.1% (28/43) for iodixanol, and 100% (2/2) for iopromide. Cross-reactivity was in the range of 59.6%-75.9% between iohexol and iodixanol, 75.0%-77.4% between iohexol and iopromide, and 43.3%-60.0% between iodixanol and iopromide. Only 1/14 patients who were skin test and DPT negative developed a reaction on re-exposure to ICM after testing.ConclusionObjective testing for ICM hypersensitivity, particularly within 6 months of initial exposure, allows the majority of patients to be administered the same or an alternative ICM with no adverse reaction, with iodixanol having the lowest cross-reactivity.</p>","PeriodicalId":7143,"journal":{"name":"Acta radiologica","volume":" ","pages":"2841851251321476"},"PeriodicalIF":1.1000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta radiologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02841851251321476","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundWith increasing importance of iodine-based contrast media (ICM) in radiology, a label of allergy to ICM has significant impact on patient management, and objective testing for ICM allergy can help guide subsequent administration.PurposeTo correlate skin testing with drug provocation test (DPT) outcomes and determine cross-reactivity between our institution's three available ICMs.Material and MethodsEligible patients who presented to our institution's radiology department within a 3-year period with suspected ICM allergy were referred to the allergist for evaluation with skin testing ± DPT. Patients who tested negative were followed up to evaluate for any reaction after ICM re-exposure in subsequent contrast-enhanced computed tomography scans.ResultsA total of 72 cases underwent testing. Concordance between skin testing and DPT was 85.7% (6/7) for iohexol, 65.1% (28/43) for iodixanol, and 100% (2/2) for iopromide. Cross-reactivity was in the range of 59.6%-75.9% between iohexol and iodixanol, 75.0%-77.4% between iohexol and iopromide, and 43.3%-60.0% between iodixanol and iopromide. Only 1/14 patients who were skin test and DPT negative developed a reaction on re-exposure to ICM after testing.ConclusionObjective testing for ICM hypersensitivity, particularly within 6 months of initial exposure, allows the majority of patients to be administered the same or an alternative ICM with no adverse reaction, with iodixanol having the lowest cross-reactivity.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta radiologica
Acta radiologica 医学-核医学
CiteScore
2.70
自引率
0.00%
发文量
170
审稿时长
3-8 weeks
期刊介绍: Acta Radiologica publishes articles on all aspects of radiology, from clinical radiology to experimental work. It is known for articles based on experimental work and contrast media research, giving priority to scientific original papers. The distinguished international editorial board also invite review articles, short communications and technical and instrumental notes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信